Costanzi J J
Cancer Treat Rep. 1976 Feb;60(2):189-92.
In a phase I study, the best antitumor/toxicity ratio for DTIC was reported to be at a dose of 250 mg/m2/day X 5 repeated at 28-day intervals. Nausea, vomiting, leukopenia, and thrombocytopenia were the major toxic effects noted. The best responses were seen in disseminated melanoma (19%), various sarcomas (22%), and Hodgkin's disease. A subsequent phase II study in refractory lymphomas showed a response rate in Hodgkin's disease of 56%. In disseminated melanomas, DTIC was then combined with vincristine and BCNU and demonstrated a response rate of 23% which did not improve with the addition of chlorpromazine (23%). A response rate of 31% was seen with the combination of DTIC, BCNU, and hydroxyurea which did not improve with the addition of vincristine (30%). Responders had a more significant survival rate as compared to nonresponders.
在一项I期研究中，据报道达卡巴嗪（DTIC）的最佳抗肿瘤/毒性比出现在剂量为250 mg/m²/天，共5天，每28天重复一次的情况下。观察到的主要毒性作用包括恶心、呕吐、白细胞减少和血小板减少。在播散性黑色素瘤（19%）、各种肉瘤（22%）和霍奇金病中观察到最佳反应。随后一项针对难治性淋巴瘤的II期研究显示，霍奇金病的缓解率为56%。在播散性黑色素瘤中，DTIC随后与长春新碱和卡莫司汀（BCNU）联合使用，显示缓解率为23%，添加氯丙嗪后缓解率未提高（23%）。DTIC、BCNU和羟基脲联合使用时缓解率为31%，添加长春新碱后缓解率未提高（30%）。与无反应者相比，有反应者的生存率更高。
